Return to Trial Database

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Status

Enrollment Closed

Cancer Type(s)

Study Contact

studies@hoosiercancer.org

Publications

Randomized phase II trial of pembrolizumab/carboplatin vs. carboplatin alone for breast cancer with chest wall recurrence: TBCRC044

Trial Locations

All sites in which the trial TBCRC044 being conducted in.

Dana-Farber Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

The University of Chicago Medicine Comprehensive Cancer Center

UC San Francisco

UPMC Hillman Cancer Center

Vanderbilt-Ingram Cancer Center